文献速递造血干细胞移植与细胞治疗

霉酚酸酯预防疗程对单倍体相合造血干细胞移植后急性移植物抗宿主病的影响

[Impact of mycophenolate mofetil prophylaxis duration on acute graft-versus-host disease after haploidentical stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

回顾性分析237例接受「北京方案」单倍体相合造血干细胞移植的标危成人血液肿瘤患者,比较长疗程与短疗程霉酚酸酯预防对急性GVHD的影响。短疗程组Ⅱ~Ⅳ度急性GVHD发生率低于长疗程组(17.6%比31.1%,P=0.018),多因素分析未发现疗程与Ⅱ~Ⅳ度急性GVHD相关,两组CMV血症、EBV血症、出血性膀胱炎及总生存差异均无统计学意义。

要点

  • 短疗程组Ⅱ~Ⅳ度急性GVHD发生率为17.6%,长疗程组为31.1%(P=0.018)。
  • 多因素分析未发现霉酚酸酯预防疗程对Ⅱ~Ⅳ度急性GVHD有显著影响。
  • 两组CMV血症、EBV血症、出血性膀胱炎发生率及总生存率差异均无统计学意义。

核心结论

  • 短疗程霉酚酸酯预防未增加「北京方案」单倍体相合造血干细胞移植患者急性GVHD发生率,对总生存亦无显著影响,可能是一种安全可行的方案。

研究设计与样本

  • 回顾性分析2016年9月至2017年3月在北京大学血液病研究所接受单倍体相合造血干细胞移植的237例标危成人(≥14岁)血液肿瘤患者。
  • 长疗程组102例,短疗程组135例;长疗程组霉酚酸酯500 mg/d口服,-9 d开始,+30 d减半,+45~+60 d停药,合并CMV血症、EBV血症或迟发出血性膀胱炎者提前停用。
  • 短疗程组霉酚酸酯500 mg/d口服,-9 d开始,中性粒细胞植活后停药。

主要发现

  • 长疗程组与短疗程组霉酚酸酯中位用药时间分别为27(7~71)d与15(9~24)d。
  • 长疗程组与短疗程组Ⅱ~Ⅳ度急性GVHD发生率分别为31.1%与17.6%(P=0.018),短疗程组较低。
  • 长疗程组与短疗程组Ⅲ/Ⅳ度急性GVHD发生率分别为7.4%与7.8%(P=0.900)。
  • 多因素分析未发现霉酚酸酯预防疗程长短对Ⅱ~Ⅳ度急性GVHD有显著影响。
  • 两组CMV血症、EBV血症、出血性膀胱炎发生率及总生存率差异均无统计学意义(P值均>0.05)。

关键数值与推荐

  • 长疗程组与短疗程组Ⅱ~Ⅳ度急性GVHD发生率分别为31.1%与17.6%(P=0.018)。
  • 长疗程组与短疗程组Ⅲ/Ⅳ度急性GVHD发生率分别为7.4%与7.8%(P=0.900)。
  • 长疗程组与短疗程组霉酚酸酯中位用药时间分别为27(7~71)d与15(9~24)d。
  • 两组CMV血症、EBV血症、出血性膀胱炎发生率及总生存率差异均无统计学意义(P值均>0.05)。

临床怎么用

  • 作者认为短疗程霉酚酸酯预防可能是一种安全可行的方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the impact of mycophenolate mofetil (MMF) prophylaxis duration on acute graft-versus-host disease (aGVHD) after haploidentical stem cell transplantation (haplo-HSCT) using 'Beijing Protocol'. Methods: Adult patients (≥14 years) received haplo-HSCT in Peking University Institute of Hematology from Sep, 2016 to Mar, 2017 were retrospectively reviewed if they fulfilled the criterias: ①diagnosed with hematological maligancies; ②standard-risk status at haplo-HSCT. A total of 237 patients [including 102 patients with long MMF duration (defined as started on day -9 with 100 mg/d, adjusted to 500 mg/d from day +30 and discontinued on day +45 to +60 or occurrence of CMV/EBV reactivation or late-onset hemorrhagic cytitis), and 135 patients with short MMF duration (defined as started on day -9 with 500 mg/d and discontinued on the day achieved neutrophil engraftment)] were reviewed. The incidence of aGVHD, virus infection and overall survival (OS) were compared between the two groups. Results: The median durations of MMF prophylaxis of long and short duration groups were 27(7-71) and 15(9-24) days, respectively after haplo-HSCT. There were no differences of baseline characteristics (including sex, patient age, disease, mismatched HLA loci, donor-recipient relation, donor-recipient sex and donor age) between the two groups. The incidences of the grade Ⅱ-Ⅳ and Ⅲ/Ⅳ aGVHD in long and short duration groups were 31.1% versus 17.6% (P=0.018) and 7.4% verus 7.8% (P=0.900), respectively. The duration of MMF prophylaxis was not found to be associated with gradeⅡ-Ⅳ aGVHD by the multivariate analysis. There were no significant differences in terms of CMV viremia, EBV viremia, hemorrhagic cytitis and OS between the two groups. Conclusion: Prophylaxis with short duration MMF in the setting of 'Beijing protocol' haplo-SCT was not associated with increased acute GVHD with no impact on OS, which indicated that short duration MMF might be a feasible GVHD prophylaxis regimen. 目的: 分析霉酚酸酯(MMF)预防疗程对于"北京方案"单倍体相合造血干细胞移植(haplo-HSCT)后急性移植物抗宿主病(GVHD)的影响。 方法: 回顾性分析2016年9月至2017年3月在北京大学血液病研究所接受haplo-HSCT的237例标危成人(≥14岁)血液肿瘤患者,男140例(59.1%),女97例(40.9%),中位年龄30(14~60)岁。根据MMF疗程分为长疗程组(MMF 500 mg/d口服,-9 d开始,+30 d减半,+45~+60 d停药,合并CMV血症、EBV血症或迟发出血性膀胱炎者提前停用)和短疗程组(MMF 500 mg/d口服,-9 d开始,中性粒细胞植活后停药)。 结果: 长疗程组(102例)、短疗程组(135例)MMF中位用药时间分别为27(7~71)、15(9~24)d。两组患者在性别、年龄、疾病类型、HLA不合位点、供受者关系、供受者血型、供者性别、供者年龄方面差异均无统计学意义。长疗程组、短疗程组Ⅱ~Ⅳ度急性GVHD发生率分别为31.1%、17.6%(P=0.018)、Ⅲ/Ⅳ度急性GVHD发生率分别为7.4%、7.8%(P=0.900)。多因素分析未发现MMF预防疗程长短对Ⅱ~Ⅳ度急性GVHD有显著影响。两组CMV血症、EBV血症、出血性膀胱炎发生率及总生存率差异均无统计学意义(P值均>0.05)。 结论: 短疗程MMF预防并未增加"北京方案"haplo-HSCT患者急性GVHD发生率,对总生存亦无显著影响,可能是一种安全可行的方案。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Sun YQ, Huang XJ, Xu LP, et al. [Impact of mycophenolate mofetil prophylaxis duration on acute graft-versus-host disease after haploidentical stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29779322. doi:10.3760/cma.j.issn.0253-2727.2018.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。